Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.56 |
| ▸ | MAOB | P27338 | 6/20 | 0.52 |
| ▸ | MAOA | P21397 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14838111 | 1.00 | CALML3 (0.56) | CALML3MAOBMAOACYP2C19CYP3A4 | |
| SCHEMBL13484703 | 0.90 | F10 (0.46) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL10196142 | 0.90 | CALML3 (0.44) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL15458115 | 0.87 | CALML3 (0.42) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL24142630 | 0.87 | CALML3 (0.42) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL14838114 | 0.87 | CALML3 (0.41) | CALML3MAOBMAOACYP2C19CYP3A4 | |
| SCHEMBL17801942 | 0.87 | MAOA (0.45) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL1031591 | 0.86 | MAOA (0.62) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL17801943 | 0.86 | MAOA (0.45) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL1031592 | 0.86 | MAOA (0.62) | CALML3MAOBMAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348447-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023122759-A2 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | AKAGERA MEDICINES, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210403463-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
| CN-108368139-B | Substituted oxazolidinone compounds and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2020-12-18 | — | — | CN | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| EP-2762480-A1 | OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| EP-2692727-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LegoChem Biosciences, Inc. (KR) | 2014-02-05 | — | — | EP | disclosed |
| WO-2013044845-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | 山东轩竹医药科技有限公司 (CN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013044865-A1 | OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING | 山东轩竹医药科技有限公司 (CN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012134188-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 (KR) | 2012-10-04 | — | — | WO | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403463-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | CALML3 2409/4885MAOB 1216/4885MAOA 1751/4885 |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | OXA1L, PAM, ABCC1 | CALML3 4088/4885MAOB 2328/4885MAOA 3122/4885 |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | CALML3 2409/4885MAOB 1216/4885MAOA 1751/4885 |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | OXA1L, THPO, TBCD | CALML3 2394/4885MAOB 1447/4885MAOA 1955/4885 |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | CALML3 1652/4885MAOB 427/4885MAOA 853/4885 |
| US-11566023-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | OXA1L, THPO, TBCD | CALML3 2409/4885MAOB 1216/4885MAOA 1751/4885 |
| US-20230348447-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | CALML3 2409/4885MAOB 1216/4885MAOA 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.